Epinephrine-Lidocaine HCl — Class III drug recall D-0040-2024
Terminated recall by Imprimis NJOF, LLC, reported 2023-10-11, distributed nationwide. Subpotent: Failing Test Results for Epinephrine
| Recall number | D-0040-2024 |
|---|---|
| Product type | Drug |
| Classification | Class III |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Imprimis NJOF, LLC, Ledgewood, NJ, United States |
| Recall initiated | 2023-10-03 |
| Classified | 2023-10-05 |
| Reported by FDA | 2023-10-11 |
| Terminated | 2025-03-21 |
| Distributed | Nationwide (US) |
| Reason classes | potency |
| NDC | 71384-0640-01 |
| Lot numbers | 23APR018 |
Product
Epinephrine-Lidocaine HCl (0.25mg/mL and 7.5mg/mL) 1mL Single Use Intraocular injection Preservative Free NDC 71384-640-01 Not for resale. Office use only. Lot: 23APR018 Date Compounded: 24APR2023 Expires on: 17APR2024. In case of adverse event contact: www.fda.gov/medwatch or (800)-FDA-1088 Imprimis NJOF, LLC. 1705 Route 46 West, Unit 6B, Ledgewood, NJ, 07852 (844) 446-6979
Reason for recall
Subpotent: Failing Test Results for Epinephrine
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0040-2024. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.